Patients Book a Consult Pharmacists Order here

‘Unapproved’ medicinal cannabis: changes to prescribing pathway

Changes to the prescribing pathway allow a more streamlined process for prescribing ‘unapproved’ medicinal cannabis for your patients. Find out more.


Key Points

Authorised Prescriber (AP) and Special Access Scheme (SAS) applications for ‘unapproved’ medicinal cannabis products are now made by active ingredient rather than brand name.
Five new categories stratify medicinal cannabis products by cannabinoid content.


Prescribers no longer need to submit a separate application to the Therapeutics Goods Administration (TGA) each time they change the product prescribed. This allows greater flexibility when substituting products within the active ingredient category and dosage form for which approval has been granted.


A published list of medicinal cannabis products is available on the TGA website.


From 28 April 2022, extemporaneous compounding of medicinal cannabis products can only occur with a prescription with AP or SAS approval.



We offer comprehensive information on medicinal cannabis products, dosages, and interactions to support pharmacists in their role of providing patients with accurate information and best possible care.

Order Medicinal Cannabis

Connect with Australia’s premier full-service wholesale distributor of medicinal cannabis products.

Read More

Request Product List

Contact our team today and request your product list documents via email.

Read More

Speak to our team

Not sure where to start? Speak with our friendly team and have your questions answered.

Read More